Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > $Value to Insiders from a Potential Buyout

<< Previous

Bullboard Posts

Next >>

Comment by fox7mfon Jan 10, 2023 7:32pm

169 Views

Post# 35214678

RE:RE:RE:$Value to Insiders from a Potential Buyout

Well, in any event, thanks for the work you put in here Proboscises...greatly appreciated. We must be in the home stretch now & with the 90 day exclusivity quickly evaporating, a PR could drop any day. GLTA.

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023